M. Hanawa

Randomized trial of granulocyte colony-stimulating factor for spinal cord injury

Masahiko Watanabe, D. Togawa, Yasuhisa Fujii, 2021, Brain : a journal of neurology.

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase

Yasuhisa Fujii, A. Hata, T. Ariga, 2019, The Lancet.

Study protocol for the G-SPIRIT trial: a randomised, placebo-controlled, double-blinded phase III trial of granulocyte colony-stimulating factor-mediated neuroprotection for acute spinal cord injury

Masahiko Watanabe, D. Togawa, Yasuo Ito, 2018, BMJ Open.

Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study

Yasuhisa Fujii, K. Murata, H. Hanaoka, 2022, BMJ Open.

A phase III, multicenter, single-arm study to assess the utility of indocyanine green fluorescent lymphography in the treatment of secondary lymphedema.

Yasuhisa Fujii, Shinsuke Akita, N. Mitsukawa, 2021, Journal of vascular surgery. Venous and lymphatic disorders.

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results

Yasuhisa Fujii, K. Murata, H. Ishikawa, 2023, International journal of molecular sciences.